SCHEMBL9914930

SCHEMBL9914930

CCCCCC(=O)N1CCN(C(=O)C(=O)c2c[nH]c3c(-n4ccnn4)ncc(F)c23)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2B6 P20813 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
GNAI3 P08754 2/20 0.33
GNAI1 P63096 2/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
HIF1A Q16665 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9914892 0.86 CYP3A4 (0.39) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9284939 0.86 CYP3A4 (0.39) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914889 0.85 ALDH1A1 (0.37) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914921 0.84 CYP3A4 (0.41) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914893 0.83 CYP3A4 (0.40) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914929 0.83 CYP3A4 (0.40) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL12151917 0.82 CYP3A4 (0.44) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914932 0.81 CYP3A4 (0.39) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL9914934 0.81 CYP3A4 (0.39) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6
SCHEMBL15273622 0.81 CYP3A4 (0.39) CYP3A4CYP2C9CYP1A2CYP2C8CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646439-B1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-25 EP disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
WO-2012075235-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS NAPA, ASNS, CD4 CYP3A4 164/4885CYP2C9 500/4885CYP1A2 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.